A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Eisai Inc.
Eisai Inc.
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Henan Cancer Hospital
Takeda
Rigshospitalet, Denmark
Brown University
Sanofi
Barbara Ann Karmanos Cancer Institute
Peking University First Hospital
SWOG Cancer Research Network
Checkpoint Therapeutics, Inc.
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
National Institutes of Health Clinical Center (CC)
Montefiore Medical Center
Calithera Biosciences, Inc
Genprex, Inc.
AbbVie
Peking University First Hospital
AbbVie
Consorzio Oncotech
National Institutes of Health Clinical Center (CC)
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Eli Lilly and Company
University of Arizona
AbbVie
Amgen
Stanford University
Boehringer Ingelheim
Zhejiang University
M.D. Anderson Cancer Center
GlaxoSmithKline
University of Kentucky
National Cancer Institute (NCI)
Wales Cancer Trials Unit
Geriatric Oncology Consortium